At the BIO CEO & Investor Conference in New York yesterday, Achillion CEO Michael Kishbauch wrapped up his remarks on the biotech’s hepatitis C programs by making it clear that he was angling for a clean buyout for a premium that would “put a silly…
Archive for the ‘Achillion Pharmaceuticals’ Category
Hep C drug deal frenzy can’t be slowed by growing doubts
February 15th, 2012 
John Carroll 
Posted in Achillion Pharmaceuticals, Biocryst, Blog, Companies, Diagnostics, Funding, Hepatitis C, Idenix Pharmaceuticals, Inhibitex, Medical Devices, Medical Supply, Pharmaceuticals, Pharmasset, Startups, Universities, Videos 
Tags: biotech food social media 
Comments OffIdenix gets good news on hep C trial, but can’t compete with Gilead
February 3rd, 2012 John Carroll Idenix put out the news this morning that the FDA had lifted a partial hold on its hepatitis C drug IDX184–and then watched its share price slide.
In a sign of just how volatile the whole hepatitis C arena has become after back-to-back blockbuster buy…
Posted in Achillion Pharmaceuticals, Blog, Companies, Diagnostics, Funding, Gilead Sciences, Hepatitis C, Idenix Pharmaceuticals, IDX184, Medical Devices, Medical Supply, Pharmaceuticals, Startups, Universities, Videos Tags: biotech food social media Comments OffWho’s next on hep C biotech buyout hit list?
November 22nd, 2011 John Carroll After the big biotech deal comes the big biotech buzz. And one of the big questions on everyone’s mind after Gilead Sciences ($GILD) announced its $11 billion deal to acquire Pharmasset is, “Who’s next?” Would Inhibitex, Achillion or Idenix be the next…
Posted in Achillion Pharmaceuticals, Blog, Companies, Diagnostics, Funding, Gilead Sciences, Idenix Pharmaceuticals, Inhibitex, Medical Devices, Medical Supply, Pharmaceuticals, Pharmasset, Startups, Universities, Videos Comments OffAchillion Pharma CEO talks up sale amid Hep C trials
November 18th, 2011 Ryan McBride Achillion Pharmaceuticals CEO Michael Kishbauch told Bloomberg that his drug development group has entered serious talks with potential partners and parties interested in buying his company, with the firm’s board of directors preferring the latter. “We…
Posted in Achillion Pharmaceuticals, Blog, Companies, Diagnostics, Funding, Hepatitis C, Medical Devices, Medical Supply, Pharmaceuticals, Startups, Universities, Videos Comments Off